ALS treatment PrimeC slows disease progression by 36% phase 2b trial results show July 2, 2024 AutoBot News 0 NeuroSense Therapeutics has announced positive phase 2b results for a drug combination designed to treat amyotrophic lateral sclerosis (ALS).
